EyePoint Pharmaceuticals, Inc. — Director's Dealing 2022

Sep 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2022-09-07

Reporting Person: Duker Jay S. (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-09-07	Stock Option (Right to Buy)	$9.45	A	65300.00	Acquired	2032-09-06	Common Stock (65300.00)	Direct

Footnotes

F1: The option to purchase will vest and become exercisable over a three year period as follows: 50% at the one year anniversary of grant and then ratably over the remaining twenty-four months